NEW FEATURE

Immune Checkpoint Inhibitor (ICI) Monotherapy Benefit Predictor

Available for patients with NSCLC

GUARDANT360 Liquid CDx | GUARDANT360 Liquid

Powered by INFINITY AI

THE CLINICAL CHALLENGE

For patients with non-small cell lung cancer (NSCLC) without targetable genomic alterations, immune checkpoint inhibitor (ICI)-based regimens are a first-line treatment option. However, identifying patients who may derive meaningful benefit from ICI monotherapy remains a significant clinical challenge, even with established biomarkers.[1]

A MULTIMODAL APPROACH TO HELP PREDICT ICI MONOTHERAPY BENEFIT

The professional service portion of Guardant360® Liquid CDx, powered by InfinityAI, integrates genomic and epigenomic signals from a blood sample to provide supplemental information that may help predict benefit from ICI monotherapy in NSCLC.*

HOW THE PREDICTOR WAS DEVELOPED AND VALIDATED


478 cfDNA samples: Genomic and epigenomic signals, including TMB and MSI, were integrated to develop a multimodal ICI monotherapy predictor.[2,*]

Independent cohort: 211 cfDNA samples: The score was evaluated against real-world time to treatment discontinuation (rwTTD) and overall survival (OS).[2]


ICI HIGH BENEFIT PATIENTS EXPERIENCED SIGNIFICANTLY LONGER RWTTD AND OS

In the monotherapy validation cohort, patients predicted to have a high benefit from ICI monotherapy showed significantly longer rwTTD and overall survival than patients who were predicted to have ICI monotherapy lower benefit.

rwTTD (N=69)



OS (N=69)



*Offered as professional services only.

InfinityAI is not a standalone customer product. "Powered by InfinityAI" refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.

Important Note: Guardant360 Liquid was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.

NEW FEATURE


Immune Checkpoint Inhibitor (ICI) Monotherapy Benefit Predictor

Available for patients with NSCLC

GUARDANT360 Liquid CDx | GUARDANT360 Liquid

Powered by INFINITY AI

REPORT EXAMPLE†



Get more insight into potential ICI monotherapy benefit with Guardant360® Liquid CDx†

†Offered as professional services only.

References: 1. Vanguri RS, et al. Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. Nature Cancer. 2022;3:1151–1164. **2.** Gordon S, Wang J, Zhang S, et al. Blood-based integration of epigenomic profiles, TMB, and MSI to predict immune checkpoint inhibitor response in advanced non-small cell lung cancer (aNSCLC). Cancer Res. 2026;86(7 Suppl):Abstract 100. doi:10.1158/1538-7445.AM2026-100

InfinityAI is not a standalone customer product. "Powered by InfinityAI" refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.

Important Note: Guardant360 Liquid was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been reviewed or approved by the US FDA.

ONC-US-00686 Copyright © 2026 Guardant Health, Inc. All rights reserved

GUARDANT®